Search Results - "Xia, Jinjing"

Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients by Xiong, Liwen, Lou, Yuqing, Bai, Hao, Li, Rong, Xia, Jinjing, Fang, Wentao, Zhang, Jie, Han-Zhang, Han, Lizaso, Analyn, Li, Bing, Gu, Aiqin, Han, Baohui

“…Background The optimal neoadjuvant regimen for locally advanced resectable non-small cell lung cancer (NSCLC) remains controversial. EGFR inhibitors have…”
Get full text

Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progression by Xu, Yingqi, Xu, Jianlin, Qiao, Rong, Zhong, Hua, Xia, Jinjing, Zhong, Runbo

“…•Low expression of B lymphoid kinase predicts response to ICB therapy and is correlated with poor survival in NSCLC patients.•The oncogene B lymphoid kinase,…”
Get full text

Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer by Xia, Jinjing, Bai, Hao, Yan, Bo, Li, Rong, Shao, Minhua, Xiong, Liwen, Han, Baohui

“…Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are widely applied to treat EGFR-mutant non-small cell lung cancer (NSCLC). BIM is a…”
Get full text

Results from the IMpower132 China cohort: Atezolizumab plus platinum‐based chemotherapy in advanced non‐small cell lung cancer by Lu, Shun, Fang, Jian, Wang, Ziping, Fan, Yun, Liu, Yunpeng, He, Jianxing, Zhou, Jianying, Hu, Jie, Xia, Jinjing, Liu, Wenxin, Shi, Jane, Yi, Jing, Cao, Lejie

“…Background The global Phase III IMpower132 study evaluating atezolizumab plus pemetrexed and carboplatin or cisplatin (APP) versus pemetrexed plus carboplatin…”
Get full text

The essential roles of m6A RNA modification to stimulate ENO1-dependent glycolysis and tumorigenesis in lung adenocarcinoma by Ma, Lifang, Xue, Xiangfei, Zhang, Xiao, Yu, Keke, Xu, Xin, Tian, Xiaoting, Miao, Yayou, Meng, Fanyu, Liu, Xiaoxin, Guo, Susu, Qiu, Shiyu, Wang, Yikun, Cui, Jiangtao, Guo, Wanxin, Li, You, Xia, Jinjing, Yu, Yongchun, Wang, Jiayi

“…Abstract Background Lung adenocarcinoma (LUAD)  is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies…”
Get full text

Treatment strategy, overall survival and associated risk factors among patients with unresectable stage IIIB/IV non-small cell lung cancer in China (2015–2017): A multicentre prospective study by Shi, Yuankai, Zhang, Xin, Wu, Gang, Xu, Jianping, He, Yong, Wang, Dong, Huang, Cheng, Chen, Mingwei, Yu, Ping, Yu, Yan, Li, Wei, Li, Qi, Hu, Xiaohua, Xia, Jinjing, Bu, Lilian, Yin, Angela, Zhou, Yigong

“…There are limited studies on treatment and survival analysis among patients with unresectable Stage IIIB or IV non-small cell lung cancer (NSCLC) in routine…”
Get full text

Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy by Yu, Lian, Hu, Yaohua, Xu, Jianlin, Qiao, Rong, Zhong, Hua, Han, Baohui, Xia, Jinjing, Zhong, Runbo

“…Treatments for NSCLC patients with EGFR‐TKI resistance are limited. Given that immunotherapy and antiangiogenic agents may have synergistic antitumor effects,…”
Get full text

Targeting SLC3A2 subunit of system XC− is essential for m6A reader YTHDC2 to be an endogenous ferroptosis inducer in lung adenocarcinoma by Ma, Lifang, Zhang, Xiao, Yu, Keke, Xu, Xin, Chen, Tianxiang, Shi, Yi, Wang, Yikun, Qiu, Shiyu, Guo, Susu, Cui, Jiangtao, Miao, Yayou, Tian, Xiaoting, Du, Lutao, Yu, Yongchun, Xia, Jinjing, Wang, Jiayi

“…The m6A reader YT521-B homology containing 2 (YTHDC2) has been identified to inhibit lung adenocarcinoma (LUAD) tumorigenesis by suppressing solute carrier…”
Get full text

YAP 5-methylcytosine modification increases its mRNA stability and promotes the transcription of exosome secretion-related genes in lung adenocarcinoma by Yu, Wenjun, Zhang, Congcong, Wang, Yikun, Tian, Xiaoting, Miao, Yayou, Meng, Fanyu, Ma, Lifang, Zhang, Xiao, Xia, Jinjing

“…YAP is a transcriptional co-activator with critical roles in tumorigenesis. However, its upstream regulatory mechanism, especially how its mRNA stability is…”
Get full text

High resolution melting curve method for detection of BIM deletion by Xia, Jinjing, Bai, Hao, Xiong, Liwen, Li, Rong, Yan, Bo, Shao, Minhua, Han, Baohui

“…The aim of this study is to establish a HRM (high resolution melting curve) method for detection of deletion in human BIM gene and to detect this site deletion…”
Get full text

ISGylation of EMD promotes its interaction with PDHA to inhibit aerobic oxidation in lung adenocarcinoma by Zhang, Congcong, Cui, Jiangtao, Cao, Leiqun, Tian, Xiaoting, Miao, Yayou, Wang, Yikun, Qiu, Shiyu, Guo, Wanxin, Ma, Lifang, Xia, Jinjing, Zhang, Xiao

“…Abnormal nuclear structure caused by dysregulation of skeletal proteins is a common phenomenon in tumour cells. However, how skeletal proteins promote…”
Get full text

Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker by Zhou, Qing, Wu, Lin, Jiang, Bo, Du, Yingying, Wang, Buhai, Hu, Xiaohua, He, Yong, Zhao, Mingfang, Yao, Yu, Cui, Jiuwei, Dong, Xiaorong, Zhang, Haibo, Ma, Rui, Wang, Huijuan, Zhang, Jian, Xia, Jinjing, Zhang, Yanni, Hayslip, John W., Zhu, Andrew X., Wu, Yi-Long

“…2570 Background: CD73 is a rate-limiting enzyme in adenosine pathway promoting immune suppression in tumor microenvironment. The role of CD73 as a novel target…”
Get full text

Novel ETV1 mutation in small cell lung cancer transformation resistant to EGFR tyrosine kinase inhibitors by Zhou, Yan, Bai, Hao, Xia, Jinjing, Xu, Wang-Yang, Cheng, Lei, Xiong, Liwen

“…Non-small cell lung cancer (NSCLC) patients harboring mutations in the epidermal growth factor receptor ( ) gene respond dramatically to tyrosine kinase…”
Get full text

Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK -positive advanced non-small cell lung cancer by Yu, Hui, Sun, Si, Hu, Xingjiang, Xia, Jinjing, Wang, Jialei, Chen, Haiquan

“…The incidence of lung cancer is increasing in China, in contrast to trends in Western countries, due to the increasing numbers of smokers and high levels of…”
Get full text

IMpower210: A phase III study of second-line atezolizumab vs. docetaxel in East Asian patients with non-small cell lung cancer by Wu, Yi-Long, Lu, Shun, Chen, Gongyan, He, Jianxing, Feng, Jifeng, Zhang, Yiping, Jiang, Liyan, Pan, Hongming, Chang, Jianhua, Fang, Jian, Cai, Amy, Bu, Lilian, Shi, Jane, Xia, Jinjing

“…IMpower210 (NCT02813785) explored the efficacy and safety of single-agent atezolizumab docetaxel as second-line treatment for advanced non-small cell lung…”
Get full text

The Clinical Analysis of 21 Patients with Lymphoepithelioma-like Carcinoma after Operation. by Xia, Jinjing, Jiang, Liyan, Zhang, Jie, Miao, Qian, Xin, Yu, Zhong, Runbo, Zhao, Yizhuo, Han, Baohui

“…Lung lymphoepithelioma-like carcinoma is a rare subtype of large cell carcinomas of the lung. The aim of this study is to retrospectively analyze the clinical…”
Get full text

The essential roles of m 6 A RNA modification to stimulate ENO1-dependent glycolysis and tumorigenesis in lung adenocarcinoma by Ma, Lifang, Xue, Xiangfei, Zhang, Xiao, Yu, Keke, Xu, Xin, Tian, Xiaoting, Miao, Yayou, Meng, Fanyu, Liu, Xiaoxin, Guo, Susu, Qiu, Shiyu, Wang, Yikun, Cui, Jiangtao, Guo, Wanxin, Li, You, Xia, Jinjing, Yu, Yongchun, Wang, Jiayi

“…Lung adenocarcinoma (LUAD)  is the most common subtype of lung cancer. Patient prognosis is poor, and the existing therapeutic strategies for LUAD are far from…”
Get full text

Targeting SLC3A2 subunit of system X C - is essential for m 6 A reader YTHDC2 to be an endogenous ferroptosis inducer in lung adenocarcinoma by Ma, Lifang, Zhang, Xiao, Yu, Keke, Xu, Xin, Chen, Tianxiang, Shi, Yi, Wang, Yikun, Qiu, Shiyu, Guo, Susu, Cui, Jiangtao, Miao, Yayou, Tian, Xiaoting, Du, Lutao, Yu, Yongchun, Xia, Jinjing, Wang, Jiayi

“…The m A reader YT521-B homology containing 2 (YTHDC2) has been identified to inhibit lung adenocarcinoma (LUAD) tumorigenesis by suppressing solute carrier…”
Get full text

Clinical Study of Erlotinib in the Treatment of Patients with Advanced Stage Non-small Cell Lung Cancer by XIA, Jinjing, JIAN, Liyan, ZHANG, Jie, MIAO, Qian, Yu, XIN, ZHONG, Runbo, ZHAO, Yizhuo, HAN, Baohui

“…背景与目的 厄洛替尼在NSCLC患者中已有广泛应用，并能使部分NSCLC患者明显获益。本研究探讨厄洛替尼单药一线或二、三线治疗晚期非小细胞肺癌的临床疗效及毒副反应。方法 研究对象为2007年6月-2008年8月接受过化疗或未化疗过的IIIb或IV期非小细胞肺癌患者，给予厄洛替尼口服150…”
Get full text

The Clinical Analysis of 21 Patients with Lymphoepithelioma-like Carcinoma after Operation by XIA, Jinjing, JIAN, Liyan, ZHANG, Jie, MIAO, Qian, Yu, XIN, ZHONG, Runbo, ZHAO, Yizhuo, HAN, Baohui

“…背景与目的 原发性肺淋巴上皮瘤样癌（lymphoepithelioma-like carcinoma, LELC）是一种少见的肺部肿瘤，为肺大细胞癌的一个亚型。本研究回顾性分析LELC患者的临床特征、手术方法、实验室指标、术后放化疗及预后。方法…”
Get full text